Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557569 · ClinicalTrials.gov registry record · Phase 1
Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01557569 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 20 participants.
The verdict
NCT01557569, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the ability of atomoxetine compared to placebo to increase time to relapse in methamphetamine dependent volunteers. Our hypothesis is that atomoxetine will increase time before (if) the participant relapses.
Interventions
- DRUG placebo
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01557569
The ClinicalTrials.gov registry entry for NCT01557569 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01557569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01557569 about?
NCT01557569 is a clinical study titled "Clinical Efficacy of Atomoxetine for Methamphetamine Dependence". The purpose of this study is to examine the ability of atomoxetine compared to placebo to increase time to relapse in methamphetamine dependent volunteers. Our hypothesis is that atomoxetine will increase time before (if) the participant relapses.
What is the current status of trial NCT01557569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-04. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01557569?
The interventions under investigation include: placebo (DRUG), Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT01557569?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.